Thoracic cancer · 2026
Impact of Anti-Inflammatory Drug Therapy on the Efficacy of First-Line Atezolizumab Treatment in Patients With Advanced Non-Small Cell Lung Cancer: An Integrated Analysis of Five Randomized Controlled Trials.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Takada Kazuki, Cortellini Alessio, Takamori Shinkichi, Mizuki Fumitaka, Pinato David J, Shimokawa Mototsugu
Аннотация
INTRODUCTION: Anti-inflammatory agents including acetaminophen (APAP) and non-steroidal anti-inflammatory drugs (NSAIDs) may blunt anti-tumor immunity.
METHODS: We performed a patient-level cross-trial analysis of five randomized controlled studies (IMpower110, IMpower130, IMpower131, IMpower132, and IMpower150) that assessed the efficacy of first-line atezolizumab therapy in advanced non-small cell lung cancer (NSCLC). We investigated whether APAP/NSAIDs exposure influenced progression-free survival (PFS) and overall survival (OS) in both atezolizumab-treated and non-atezolizumab-treated cohorts using forest plot analysis.
RESULTS: In 3781 patients, APAP exposure was 15.4% (583/3781) and NSAIDs use was 33.9% (1282/3781). APAP use was associated with worse PFS and OS in both the atezolizumab and non-atezolizumab groups (PFS with atezolizumab: hazard ratio [HR] = 1.18, 95% confidence interval [CI]: 0.97-1.43; PFS without atezolizumab: HR = 1.23, 95% CI: 1.05-1.43; OS with atezolizumab: HR = 1.13, 95% CI: 0.98-1.30; OS without atezolizumab: HR = 1.31, 95% CI: 1.04-1.65). NSAIDs use was not associated with differences in PFS or OS in the atezolizumab group but was linked to worse PFS and OS in the non-atezolizumab group (PFS with atezolizumab: HR = 0.98, 95% CI: 0.89-1.08; PFS without atezolizumab: HR = 1.18, 95% CI: 1.03-1.34; OS with atezolizumab: HR = 1.01, 95% CI: 0.91-1.13; OS without atezolizumab: HR = 1.27, 95% CI: 1.10-1.46). After excluding patients on baseline proton pump inhibitors, a significant interaction between NSAIDs use and treatment modality was observed in the multivariable analysis of OS (p = 0.0140), with no interaction for APAP use (p = 0.6707).
CONCLUSION: Neither APAP nor NSAIDs exposure influenced atezolizumab efficacy.
METHODS: We performed a patient-level cross-trial analysis of five randomized controlled studies (IMpower110, IMpower130, IMpower131, IMpower132, and IMpower150) that assessed the efficacy of first-line atezolizumab therapy in advanced non-small cell lung cancer (NSCLC). We investigated whether APAP/NSAIDs exposure influenced progression-free survival (PFS) and overall survival (OS) in both atezolizumab-treated and non-atezolizumab-treated cohorts using forest plot analysis.
RESULTS: In 3781 patients, APAP exposure was 15.4% (583/3781) and NSAIDs use was 33.9% (1282/3781). APAP use was associated with worse PFS and OS in both the atezolizumab and non-atezolizumab groups (PFS with atezolizumab: hazard ratio [HR] = 1.18, 95% confidence interval [CI]: 0.97-1.43; PFS without atezolizumab: HR = 1.23, 95% CI: 1.05-1.43; OS with atezolizumab: HR = 1.13, 95% CI: 0.98-1.30; OS without atezolizumab: HR = 1.31, 95% CI: 1.04-1.65). NSAIDs use was not associated with differences in PFS or OS in the atezolizumab group but was linked to worse PFS and OS in the non-atezolizumab group (PFS with atezolizumab: HR = 0.98, 95% CI: 0.89-1.08; PFS without atezolizumab: HR = 1.18, 95% CI: 1.03-1.34; OS with atezolizumab: HR = 1.01, 95% CI: 0.91-1.13; OS without atezolizumab: HR = 1.27, 95% CI: 1.10-1.46). After excluding patients on baseline proton pump inhibitors, a significant interaction between NSAIDs use and treatment modality was observed in the multivariable analysis of OS (p = 0.0140), with no interaction for APAP use (p = 0.6707).
CONCLUSION: Neither APAP nor NSAIDs exposure influenced atezolizumab efficacy.